QUALITY OF LIFE IN SYSTEMIC LUPUS WOMEN WITH CUTANEOUS DAMAGE ON THE FACE: COSMETIC CAMOUFLAGE IMPACT

Cristina Costa Landi1, 2, Fabiano Miranda Moura dos Santos1, 3, Maria Velez Rocha Mamelmuk3, Thaigo Loredo e Silva3, Clara Otomi Neves3, Douglas Mansur Guerra3, Maria Fernanda Botelho Teixeira3, Claudine Lopes Santana Neiva4, Ana Flavia Madureira de Pádua Dias4, Rosane Weiss Telles4, 1Medical School, Universidade Federal de Minas Gerais, Locomotor Apparatus, Belo Horizonte, Brazil; 2Medical School, Universidade Federal of Minas Gerais, Post-graduation Programme, Belo Horizonte, Brazil; 3Medical School, Universidade Federal de Minas Gerais, Undergraduate student, Belo Horizonte, Brazil; 4Santa Casa de Misericórdia, Rheumatology Unit, Belo Horizonte, Brazil; 5Medical School, Universidade Federal de Minas Gerais, Internal Medicine, Belo Horizonte, Brazil

Background: Health-related quality of life (HRQoL) can be negatively impacted by visible skin lesions.

Objectives: To investigate the effect of cosmetic camouflage on health-related quality of life of systemic lupus erythematosus (SLE) women presenting sequelae of cutaneous manifestations on the face.

Methods: This is a randomized controlled clinical trial (Universal Trial Number: U1111-1210-2554e) with outpatients SLE women according to ACR/1997 and/or SLICC/2012 criteria, aged over 18 years old with sequelae of cutaneous lupus manifestations on the face, recruited in two tertiary centers. Exclusion criteria were: moderate to severe systemic lupus activity (SLEDAI 2k-modified >4), no understanding of the questionnaires or psychological and/or psychiatric treatment initiation or modification during the study. A final sample of 43 patients was divided into group I (cosmetic camouflage n=28) and group II (control n=15). Patients in group I were instructed to use cosmetic camouflage daily; Group II patients did not use any camouflage. SLE Quality of Life (SLEQoL) and Dermatology Quality of Life Index (DLQI) questionnaires were used to evaluate HRQoL. Higher scores meaning worse HRQoL. All patients answered the questionnaires at baseline (T0) and after 12 (±2) weeks (T1). The primary end point was a change on HRQoL after camouflage cosmetic use. Continuous variables were described as median (interquartile range). The Wilcoxon signed rank test and the Mann-Whitney U test were used for the analysis as indicated. End points were investigated per-protocol analysis, and a 2-sided p value <0.05 was considered to be significant.

Results: Both groups were similar at baseline regarding age [group I:45.0 (37.3-55.7) years old versus group II: 50.0(43.0-55.0) years old, p=0.575], disease duration [group I: 17.5 (7.3-26.5) years versus group II: 15.0 (9.0-17.0) years, p=0.452] and modified SLEDAI-2k [group I: 0 (0-2) versus group II: 2 (0-2), p=0.301]. Also, they were similar considering the sociodemographic, clinical and treatment characteristics of the disease. The DLQI and SLEQoL scores decreased in the cosmetic camouflage group from baseline: DLQI [T0: 85.0 (4.0-16.0) versus T1: 3.0 (1.0-7.5), p=0.008]; SLEQoL [T0: 118.0 (91.0-154.3) versus T1: 95.5 (76.0-135.0), p=0.003]; while there was no variation in the control group: DLQI [T0: 8.0 (3.0-12.0) versus T1: 7.0 (4.0-12.0), p=0.196]; SLEQoL [T0: 89.0 (65.0-127.0) versus T1: 95.5 (65.0-164.0), p=0.532]. The difference on the variations of HRQoL scores between groups I and II was statistically significant: ∆DLQI [group I: 3.0 (-10.8-0.0) versus group II: 1.0 (-10.6-0.0), p=0.003] and ∆SLEQoL [group I:14.5 (-33.0-0.0) versus group II:3.0 (-8.0-10.0), p=0.009]. The SLEQoL score variations were on physical function (p=0.033), humor (p = 0.033) and self-image (p=0.031) domains.

Conclusion: In this group of SLE women with low systemic disease activity and sequelae of cutaneous manifestations on the face, we observed an improvement of HRQoL after daily use of cosmetic camouflage. It is an effective intervention that should be recommended by the rheumatologists.

REFERENCES


THE EFFECTS OF ACUPUNCTURE ON XEROSTOMIA, XEROPHTHALMIA AND ANTIBODY MODIFICATION IN PATIENTS WITH SjÖGREN SYNDROME: A META-ANALYSIS

Tzu-Hao Li1, 2,3, Yen-Ying Kung4, 1, Chang-Youch Tsa4, 5, 1Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Chiayi Branch, Taichung Veterans General Hospital, Chiayi City, Taiwan, Republic of China; 2Institute of Clinical Medicine, National Yang-Ming University, Taipei City, Taiwan, Republic of China; 3Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China; 4Center for Traditional Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China; 5Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei City, Taiwan, Republic of China

Background: Xerostomia and xerophthalmia are common chief complaints among patients with Sjögren syndrome (SS) but there has been no satisfying pharmacy to relieve the associated symptoms; hence the effectiveness of other non-pharmacological interventions such as acupuncture should be assessed.

Objectives: To access the therapeutic effects of acupuncture on xerostomia and xerophthalmia in patient with SS.

Methods: We conducted a meta-analysis of randomized clinical trials (RCTs) which evaluated the effectiveness of xerostomia and xerophthalmia in SS. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Chongqing Weipu Database (CQVIP), China Academic Journals Full-text Database, AiritiLibrary, Chinese Electronic Periodicals Service (CEPS), China National Knowledge Infrastructure (CNKI) Database were searched through Oct, 2018 to select studies. Data for evaluation of subjective and objective xerostomia was extracted and was assessed with random-effects meta-analysis.

Results: After searching, a total of 680 references were yielded and five RCTs were included, covering 460 patients dry mouth resulted from SS, among whom 229 patients received acupuncture and 231 patients were control group. Acupuncture group was associated with higher subjective response rate (odds ratio 3.036, 95% confidence interval [CI] 1.828 – 5.042, P < 0.001, Fig. 1) and increased salivary flow rate (weighted mean difference [WMD] 3.066, 95% CI 2.969 – 3.164, P < 0.001, Fig. 2), as an objective marker. Regarding xerophthalmia, acupuncture group revealed less dry eye visual analog scale (VAS, WMD -1.035, 95% CI: -1.457 – -1.673, P < 0.001, Fig. 3), better Schirmer test (WMD 2.357, 95% CI: 1.021 – 3.692, P = 0.001, Fig. 4) and trend of longer break-up time (WMD 4.927, 95% CI: -0.055 – 9.908, P = 0.053, Fig. 5). In addition, two studies examined IgG levels, which were lower in the acupuncture group (WMD -166.857, 95% CI: -233.138 – -100.576, P < 0.001, Fig. 6).

Conclusion: In the present meta-analysis, acupuncture improves both subjective and objective markers of xerostomia and xerophthalmia in patients with SS and is considered as an option of non-pharmacological treatment.

REFERENCES


IMMUNOREGULATORY THERAPY EFFECTIVELY PROMOTES THE BALANCE BETWEEN TREG CELLS AND PRO-INFLAMMATORY LYMPHOCYTES IN SYSTEMIC LUPUS ERYTHEMATOSUS

Xiaojing Liu1, Nalin Lai2, Ting Cheng3, Xiaojuan Mao4, Li Xiaofeng4, 1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taixian, China; 2The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 3The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 4The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China

Background: Recent studies have reported that some drugs such as low-dose interleukin-2, rapamycin, melphalan, retinoic acid and coenzyme Q10 could promote the proliferation and functional recovery of regulatory T cells (Treg) in patients with autoimmune diseases. However, the effects on the balance of Treg cells and pro-inflammatory lymphocytes and long-term efficacy have rarely been reported.

Objectives: To evaluate the changes of peripheral lymphocyte subsets, conventional drugs and remission rate in patients with systemic lupus erythematosus (SLE) after immunomodulatory therapy.

Methods: A total of 89 patients with SLE from the Second Affiliated Hospital of Shanxi Medical University from January 2016 to April 2018 were enrolled, who were divided into well-controlled group and untargeted control group taking a full consideration of the patient’s symptoms, signs and related laboratory findings. We measured the absolute counts of B, NK, CD8+ T and helper T 1 (Th1), helper T 2 (Th2), helper T 17 (Th17) and Treg cells in peripheral blood of patients before immunomodulatory therapy and during the 3 months and 6 months of follow-up and 93 sex- and age- matched control individuals using flow cytometry. Moreover, the ratios of various cells to Treg cells were calculated.

Results: Compared with healthy controls, Treg cells in SLE patients were significantly lower before the treatment with immunomodulator, while the ratios of various pro-inflammatory lymphocytes to Treg cells (such as Th2/Treg, Th17/Treg, CD8+ T/Treg, etc.) were higher. After 3 months and 6 months with immunomodulatory therapy, the absolute number of Treg cells in peripheral blood of SLE patients increased obviously reaching to normal level. Accordingly, the ratios of various pro-inflammatory lymphocytes to Treg cells recovered. At the same time, the dose of glucocorticoid and disease-modifying antirheumatic drugs (DMARDs) decreased distinctly. Additionally, the well-controlled group was able to maintain a high remission rate, and the untargeted control group could achieve a higher response rate after immunomodulatory treatment.

Conclusion: The imbalance between pro-inflammatory lymphocytes and Treg cells caused by the significant decrease of Treg cells may be the main cause of SLE. And immunomodulatory therapy we came up with may reverse the imbalance of proinflammatory lymphocytes and Treg cells, which is an potential and effective treatment for SLE.

REFERENCES

Disclosure of Interests: None declared

VITAMIN D SUPPLEMENTATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH VITAMIN D DEFICIENCY AND INSUFFICIENCY: THE EFFECT ON DISEASE ACTIVITY, FATIGUE AND INTERFERON SIGNATURE GENE EXPRESSION

Rosalie Maqro1, Christian Saliba2, Liberto Camilleri2, Christian Scerr1, Andrew Borg1, Mater Dei Hospital, Rheumatology, Msida, Malta; 2University of Malta, Msida, Malta

Background: Vitamin D deficiency is highly prevalent among patients with systemic lupus erythematosus (SLE) [1]. Evidence from multiple studies has shown that vitamin D deficiency in SLE is associated with a higher disease activity [2]. There is conflicting evidence with regards to the relationship between fatigue and vitamin D level [3,4].

Objectives: The principal aim of this study was to establish any potential effect on the level of fatigue, disease activity (measured by SLE disease activity index-2K (SLEDAI-2K)) and interferon signature gene expression, from vitamin D supplementation to SLE patients with vitamin D deficiency or insufficiency.

Methods: 33 SLE patients, 13 with vitamin D deficiency and 20 with vitamin D insufficiency, gave informed consent to participate in this 12 month prospective study. Their participation consisted of an interview, filling out the Fatigue Severity Scale (FSS), and blood tests. The patients were advised to take vitamin D3 8000IU daily for 8 weeks if they were vitamin D deficient, or 8000IU daily for 4 weeks if they were insufficient. This was followed by 2000IU daily maintenance. The patients were reassessed after 6 and 12 months of vitamin D supplementation. RNA was extracted from whole blood taken from the patients at baseline and after 6 months of vitamin D supplementation. The expression of 12 interferon signature genes was measured in the extracted RNA by using Quantilene Plex technology. Approval to carry out this study was obtained from the University Research Ethics Committee.

Results: 87.9% of SLE patients studied were female. The mean age was 47.6 years and the mean duration of SLE was 13.8 years. Table 1 shows the results obtained for several variables at baseline, after 6 months and after 12 months. The expression of all 12 interferon signature genes measured, was noted to decrease following 6 months of vitamin D supplementation. This reached statistical significance for two of the genes measured (OAS1, p<0.014; SOCS1, p=0.003).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Time</th>
<th>Mean</th>
<th>Standard Deviation</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLEDAI-2K</td>
<td>Baseline</td>
<td>3.97</td>
<td>3.359</td>
<td>0.210</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>3.36</td>
<td>2.924</td>
<td>0.009</td>
</tr>
<tr>
<td></td>
<td>12 months</td>
<td>2.61</td>
<td>2.193</td>
<td>0.005</td>
</tr>
<tr>
<td>Anti-dsDNA level (IU/mL)</td>
<td>Baseline</td>
<td>210.31</td>
<td>234.416</td>
<td>0.032</td>
</tr>
<tr>
<td></td>
<td>12 months</td>
<td>194.08</td>
<td>214.129</td>
<td>0.030</td>
</tr>
<tr>
<td></td>
<td>24 months</td>
<td>190.50</td>
<td>208.131</td>
<td>0.030</td>
</tr>
<tr>
<td>Prednisolone daily dose (mg)</td>
<td>Baseline</td>
<td>1.93</td>
<td>3.458</td>
<td>0.043</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>2.30</td>
<td>4.089</td>
<td>0.042</td>
</tr>
<tr>
<td></td>
<td>12 months</td>
<td>1.33</td>
<td>2.931</td>
<td>0.042</td>
</tr>
<tr>
<td>FSS</td>
<td>Baseline</td>
<td>4.21</td>
<td>1.536</td>
<td>0.026</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>3.93</td>
<td>1.577</td>
<td>0.053</td>
</tr>
<tr>
<td></td>
<td>12 months</td>
<td>3.81</td>
<td>1.859</td>
<td>0.053</td>
</tr>
<tr>
<td>25-hydroxyvitamin D (ng/mL)</td>
<td>Baseline</td>
<td>21.91</td>
<td>6.336</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>32.88</td>
<td>6.594</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>12 months</td>
<td>28.48</td>
<td>9.291</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Conclusion: The results indicate that vitamin D supplementation in SLE patients who are deficient or insufficient, results in an improvement in disease activity, and possibly also in the level of fatigue. This could be explained by the decrease in the expression of interferon signature genes.

REFERENCES

Disclosure of Interests: None declared